Beta gamma counters

InformationMGCD-265 is a potent, multi-target and ATP-competitive inhibitor ofc-MetandVEGFR1/2/3withIC50of 1 nM, 3 nM/3 nM/4 nM, respectively: also inhibits Ron and Tie2. Phase 1/2.In vitroMGCD-265 is a multi-target inhibitor of receptor tyrosine

InformationLTI-291 is the first small-molecule activator ofGlucocerebrosidase(GCase)for the treatment of parkinson's disease.

LTI-291.

LTI-291.

LTI-291.

LTI-291.

LTI-291.

InformationIn vitroIbrutinib shows the potent and irreversible inhibitory effect and selectivity for Btk enzymatic activity. In BCR pathway-activated DOHH2 cell line, Ibrutinib inhibits autophosphorylation of Btk, phosphorylation of Btk/'s

InformationHS-1371 HS-1371 is a potent RIP3 kinase inhibitor with an IC50 of 20.8 nM. It binds to the ATP binding pocket of RIP3 and inhibits ATP binding to prevent RIP3 enzymatic activity in vitro.TargetsRIP3 kinase 20.8 nMIn vitroHS-1371 shows an

InformationHS-1371 HS-1371 is a potent RIP3 kinase inhibitor with an IC50 of 20.8 nM. It binds to the ATP binding pocket of RIP3 and inhibits ATP binding to prevent RIP3 enzymatic activity in vitro.TargetsRIP3 kinase 20.8 nMIn vitroHS-1371 shows an

InformationHS-1371 HS-1371 is a potent RIP3 kinase inhibitor with an IC50 of 20.8 nM. It binds to the ATP binding pocket of RIP3 and inhibits ATP binding to prevent RIP3 enzymatic activity in vitro.TargetsRIP3 kinase 20.8 nMIn vitroHS-1371 shows an

InformationHS-1371 HS-1371 is a potent RIP3 kinase inhibitor with an IC50 of 20.8 nM. It binds to the ATP binding pocket of RIP3 and inhibits ATP binding to prevent RIP3 enzymatic activity in vitro.TargetsRIP3 kinase 20.8 nMIn vitroHS-1371 shows an